For PD-1/L1 blockade therapy to induce tumor regression, preexisting antitumor CD8+ T cells that are negatively regulated by PD-1/ L1 –mediated adaptive immune resistance must be present (3, 29). The gene discussed is CD8A; the disease is neoplasm.